Are CB2 Receptors a New Target for Schizophrenia Treatment?
Abstract Schizophrenia is a complex disorder that involves several neurotransmitters such as dopamine, glutamate, and GABA. More recently, the endocannabinoid…
Abstract Schizophrenia is a complex disorder that involves several neurotransmitters such as dopamine, glutamate, and GABA. More recently, the endocannabinoid…
Abstract Current pharmacotherapy of Parkinson’s disease (PD) is palliative and unable to modify the progression of neurodegeneration. Treatments that can…
Abstract Objective: Cannabidiol (CBD), one of the non-psychotomimetic compounds of Cannabis sativa, causes anxiolytic-like effects in animals, with typical bell-shaped…
Abstract Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a compound that does not produce the…
Abstract Cannabidiol (CBD) is a component of Cannabis sativa that has a broad spectrum of potential therapeutic effects in neuropsychiatric…
Abstract Exposure to stressful situations is one of the risk factors for the precipitation of several psychiatric disorders, including Major…
Abstract Beneficial effects of cannabidiol (CBD) have been described for a wide range of psychiatric disorders, including anxiety, psychosis, and…
Abstract The purpose of this study was to investigate whether the anxiolytic effect of cannabidiol (CBD) in humans follows the…
Abstract Cannabidiol (CBD) has been established to have both acute and long-lasting effects to reduce fear memory expression. The long-lasting…
Abstract Anxiety and trauma-related disorders are psychiatric diseases with a lifetime prevalence of up to 25%. Phobias and post-traumatic stress…